Security Snapshot

Akebia Therapeutics, Inc. - Common Stock (AKBA) Institutional Ownership

CUSIP: 00972D105

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

165

Shares (Excl. Options)

118,251,483

Price

$1.61

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
AKBA on Nasdaq
Shares outstanding
263,222,327
Price per share
$1.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
118,251,483
Total reported value
$190,384,320
% of total 13F portfolios
0%
Share change
-5,283,880
Value change
-$16,095,281
Number of holders
165
Price from insider filings
$1.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • AKBA - Akebia Therapeutics, Inc. - Common Stock is tracked under CUSIP 00972D105.
  • 165 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 165 to 39 between Q4 2025 and Q1 2026.
  • Reported value moved from $190,384,320 to $2,814,381.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 165 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 00972D105?
CUSIP 00972D105 identifies AKBA - Akebia Therapeutics, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Akebia Therapeutics, Inc. - Common Stock (AKBA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% +18% $30,943,909 +$6,565,662 19,219,819 +27% BlackRock, Inc. 31 Dec 2025
STATE STREET CORP 5.2% $19,162,585 13,687,561 STATE STREET CORPORATION 31 Dec 2025
Satter Muneer A 2.6% $13,105,226 5,747,906 Satter Muneer A 31 Dec 2024

As of 31 Dec 2025, 165 institutional investors reported holding 118,251,483 shares of Akebia Therapeutics, Inc. - Common Stock (AKBA). This represents 45% of the company’s total 263,222,327 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Akebia Therapeutics, Inc. - Common Stock (AKBA) together control 37% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.3% 19,318,452 +2.8% 0% $31,102,707
VANGUARD GROUP INC 6.1% 16,016,448 +3% 0% $25,786,481
STATE STREET CORP 5.2% 13,687,561 +16% 0% $22,036,973
GEODE CAPITAL MANAGEMENT, LLC 2.4% 6,277,177 +1.5% 0% $10,107,969
GOLDMAN SACHS GROUP INC 1.8% 4,706,437 +166% 0% $7,577,364
CITADEL ADVISORS LLC 1.8% 4,665,537 +46% 0.01% $7,511,515
RENAISSANCE TECHNOLOGIES LLC 1.4% 3,593,133 -9.1% 0.01% $5,784,944
Qube Research & Technologies Ltd 1.1% 2,990,767 -6.7% 0.01% $4,815,135
CITIGROUP INC 0.93% 2,436,203 +27% 0% $3,922,287
NORTHERN TRUST CORP 0.88% 2,313,233 -7% 0% $3,724,304
BANK OF AMERICA CORP /DE/ 0.86% 2,257,411 +26% 0% $3,634,432
ACADIAN ASSET MANAGEMENT LLC 0.84% 2,199,747 +2.4% 0.01% $3,539,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 2,180,820 +0.49% 0% $3,511,120
Nantahala Capital Management, LLC 0.76% 2,000,000 0% 0.19% $3,220,000
MILLENNIUM MANAGEMENT LLC 0.63% 1,653,469 -42% 0% $2,662,085
HRT FINANCIAL LP 0.62% 1,619,336 +6430% 0.01% $2,607,000
DIMENSIONAL FUND ADVISORS LP 0.6% 1,571,012 -11% 0% $2,528,891
FEDERATED HERMES, INC. 0.49% 1,291,172 +102% 0% $2,078,787
MORGAN STANLEY 0.47% 1,228,816 -72% 0% $1,978,394
Squarepoint Ops LLC 0.46% 1,223,027 +57% 0% $1,969,073
FMR LLC 0.43% 1,125,638 +23% 0% $1,812,277
FIRST TRUST ADVISORS LP 0.36% 941,657 0% $1,516,067
BARCLAYS PLC 0.35% 923,507 -22% 0% $1,486,847
UBS Group AG 0.33% 871,534 -76% 0% $1,403,170
WELLINGTON MANAGEMENT GROUP LLP 0.3% 786,465 -9.6% 0% $1,266,209

Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 2,025,318 $2,814,381 -$291,897 $1.39 39
2025 Q4 118,251,483 $190,384,320 -$16,095,281 $1.61 165
2025 Q3 123,669,076 $337,684,321 +$36,363,104 $2.73 176
2025 Q2 108,291,108 $394,183,978 +$56,486,637 $3.64 157
2025 Q1 95,246,755 $182,865,666 +$63,362,812 $1.92 142
2024 Q4 67,845,406 $128,903,910 +$16,367,542 $1.90 120
2024 Q3 59,433,206 $78,446,645 +$886,944 $1.32 113
2024 Q2 56,272,261 $57,424,732 -$2,482,254 $1.02 100
2024 Q1 56,991,509 $104,293,412 +$2,027,480 $1.83 108
2023 Q4 54,644,403 $67,756,919 +$4,503,736 $1.24 83
2023 Q3 50,796,845 $57,906,145 +$685,292 $1.14 72
2023 Q2 50,244,290 $45,972,433 -$1,392,343 $0.92 76
2023 Q1 51,839,170 $29,049,633 -$98,488 $0.56 62
2022 Q4 52,253,997 $30,149,698 +$763,514 $0.58 70
2022 Q3 52,161,214 $16,491,885 -$1,812,681 $0.32 79
2022 Q2 57,164,176 $20,180,226 -$11,164,741 $0.35 82
2022 Q1 81,183,875 $58,271,372 -$32,826,439 $0.72 115
2021 Q4 96,816,883 $218,731,670 -$6,193,557 $2.26 128
2021 Q3 98,493,468 $283,669,170 -$32,502,791 $2.88 119
2021 Q2 106,173,637 $402,396,029 +$22,237,368 $3.79 131
2021 Q1 100,546,584 $340,303,134 -$8,611,368 $3.38 134
2020 Q4 103,249,738 $289,096,531 -$2,381,228 $2.80 134
2020 Q3 100,173,386 $251,381,270 -$415,118,712 $2.51 155
2020 Q2 111,597,128 $1,515,160,970 +$263,628,807 $13.58 184
2020 Q1 92,760,043 $703,124,581 +$65,005,544 $7.58 150
2019 Q4 84,238,825 $532,433,824 -$9,578,644 $6.32 147
2019 Q3 85,222,099 $334,110,423 -$7,128,495 $3.92 144
2019 Q2 86,927,834 $420,591,980 -$5,534,476 $4.84 145
2019 Q1 84,729,878 $693,928,655 +$34,225,709 $8.19 165
2018 Q4 81,089,428 $448,181,562 +$214,692,780 $5.53 154
2018 Q3 40,805,612 $360,286,694 -$30,324,254 $8.83 126
2018 Q2 42,400,943 $423,114,024 -$5,780,444 $9.98 136
2018 Q1 43,137,232 $411,768,819 +$80,498,894 $9.53 144
2017 Q4 33,696,160 $501,006,013 +$17,095,503 $14.87 128
2017 Q3 30,165,358 $593,266,094 +$67,324,611 $19.67 118
2017 Q2 27,265,524 $391,622,872 +$102,455,955 $14.37 115
2017 Q1 20,825,309 $191,436,543 +$23,185,087 $9.20 86
2016 Q4 20,209,985 $210,368,267 +$3,880,985 $10.41 91
2016 Q3 19,559,159 $176,944,259 +$636,790 $9.05 83
2016 Q2 19,605,356 $146,635,724 -$12,713,555 $7.48 89
2016 Q1 21,112,430 $190,508,000 +$34,261,987 $9.01 90
2015 Q4 15,836,572 $204,569,610 +$19,766,036 $12.92 88
2015 Q3 15,103,338 $145,886,918 +$23,189,587 $9.66 80
2015 Q2 12,209,438 $125,630,881 +$52,360,330 $10.29 70
2015 Q1 7,020,367 $77,139,761 -$2,020,205 $11.11 59
2014 Q4 7,115,554 $82,816,339 -$6,653,680 $11.64 55
2014 Q3 7,121,492 $157,598,296 -$855,471 $22.13 49
2014 Q2 7,180,472 $199,536,396 +$197,487,337 $27.79 50
2014 Q1 103,803 $2,030,000 +$2,030,000 $19.56 3
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .